Blair William & Co. IL Sells 5,299 Shares of Stryker Corporation (NYSE:SYK)

Key Points

• Blair William & Co. IL reduced its stake in Stryker Corporation by 0.6%, owning 926,375 shares, which represents about 1% of its investment portfolio.
• Several institutional investors, including Continuum Advisory LLC and Oakworth Capital Inc., have increased their holdings in Stryker during the first quarter of the year.
• Stryker recently reported a quarterly earnings per share of $3.13, exceeding analyst expectations of $3.07, with a revenue of $6.02 billion for the quarter.

Blair William & Co. IL cut its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 0.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 926,375 shares of the medical technology company's stock after selling 5,299 shares during the quarter. Stryker comprises about 1.0% of Blair William & Co. IL's investment portfolio, making the stock its 16th biggest holding. Blair William & Co. IL owned 0.24% of Stryker worth $344,843,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital A Wealth Management LLC acquired a new stake in Stryker during the 4th quarter worth about $26,000. Goodman Advisory Group LLC purchased a new position in Stryker during the 1st quarter valued at about $32,000. City Holding Co. grew its stake in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 74 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in Stryker during the 1st quarter valued at about $40,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Stryker during the 4th quarter valued at about $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Down 0.3%

SYK stock traded down $1.02 during midday trading on Tuesday, reaching $380.47. The stock had a trading volume of 211,563 shares, compared to its average volume of 1,444,151. The business has a fifty day simple moving average of $387.55 and a two-hundred day simple moving average of $380.36. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a market cap of $145.22 billion, a price-to-earnings ratio of 50.37, a PEG ratio of 2.77 and a beta of 0.91. Stryker Corporation has a twelve month low of $316.01 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the previous year, the company earned $2.81 EPS. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Stockholders of record on Monday, June 30th were issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Monday, June 30th. Stryker's payout ratio is 44.50%.

Analyst Upgrades and Downgrades

SYK has been the topic of several research analyst reports. Sanford C. Bernstein set a $450.00 target price on Stryker in a research note on Monday, May 5th. Roth Mkm increased their price objective on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Monday, May 5th. Citigroup reaffirmed a "buy" rating and set a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.